公开(公告)号：US20240109877A1

公开(公告)日：2024-04-04

申请号：US18187489

申请日：2023-03-21

Applicant: AbbVie Inc.

Inventor： Zhiguo Bian ,  Jason P. Burke ,  Zhaozhong J. Jia ,  Xingyu Jiang ,  Matthew H. Katcher ,  Venkat Reddy Mali ,  Violeta L. Marin ,  Elizabeth L. Noey ,  Akinori Okano ,  Alexey A. Rivkin ,  Spencer O. Scholz ,  Kevin R. Woller ,  Xianrui Zhao ,  Ashley M. Adams ,  Berenger Biannic ,  Shahab Mortezaei ,  Joshua N. Payette ,  Jeffery A. Zablocki

IPC: C07D413/14 ,  A61P35/02

CPC classification number: C07D413/14 ,  A61P35/02

Abstract: The present invention provides for compounds of formula (I)




wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.

公开(公告)号：US20190015402A1

公开(公告)日：2019-01-17

申请号：US16042447

申请日：2018-07-23

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  A61K31/4418 ,  C07D401/14 ,  A61K45/06 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K31/435 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4178 ,  C07F7/02 ,  C07D491/113 ,  C07D453/00 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D403/14 ,  A61K31/4439

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20180291029A1

公开(公告)日：2018-10-11

申请号：US15806104

申请日：2017-11-07

Applicant: AbbVie Inc.

Inventor： Neil WISHART ,  Maria A. Argiriadi ,  David J. Calderwood ,  Anna M. Ericsson ,  Bryan R. Fiamengo ,  Kristine E. Frank ,  Michael M. Friedman ,  Dawn M. George ,  Eric R. Goedken ,  Nathan S. Josephsohn ,  Biqin C. Li ,  Michael J. Morytko ,  Kent D. Stewart ,  Jeffrey W. Voss ,  Grier A. Wallace ,  Lu Wang ,  Kevin R. Woller

IPC: C07D487/14 ,  C07D513/14 ,  C07D498/14

Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

公开(公告)号：US10039754B2

公开(公告)日：2018-08-07

申请号：US15431069

申请日：2017-02-13

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K38/00 ,  A61K31/454 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4418 ,  A61K31/5377 ,  A61K31/4355 ,  A61K31/4178

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US08859584B2

公开(公告)日：2014-10-14

申请号：US13716837

申请日：2012-12-17

Applicant: AbbVie Inc.

Inventor： Kevin R. Woller ,  Gregory A. Gfesser ,  Huaqing Liu ,  Jerome F. Daanen ,  Eric A. Voight ,  Irene I. Drizin ,  Anurupa Shrestha ,  Kathleen H. Mortell ,  Philip R. Kym ,  Michael E. Kort ,  Arthur Gomtsyan

IPC: A61K31/44 ,  A61K31/35 ,  A61K31/47 ,  A61K31/17 ,  C07D215/46 ,  C07D498/02 ,  C07D311/68 ,  A61K45/06 ,  C07D311/96 ,  C07D311/04 ,  C07C275/30 ,  A61K31/192 ,  C07D311/70 ,  A61K31/353 ,  C07D491/052 ,  A61K31/436 ,  C07D215/42 ,  C07C275/32

CPC classification number: C07D311/04 ,  A61K31/17 ,  A61K31/192 ,  A61K31/353 ,  A61K31/436 ,  A61K31/47 ,  A61K45/06 ,  C07C275/30 ,  C07C275/32 ,  C07D215/42 ,  C07D215/46 ,  C07D311/68 ,  C07D311/70 ,  C07D311/96 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，Rz，A，m，n，p，q，s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：US20140256705A1

公开(公告)日：2014-09-11

申请号：US14203641

申请日：2014-03-11

Applicant: Abbvie Inc.

Inventor： Lisa A. Hasvold ,  Dachun Liu ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Carol K. Wada ,  Kevin R. Woller

IPC: A61K31/5377 ,  A61K31/437 ,  A61K31/519 ,  A61K31/497 ,  C07D487/04 ,  A61K31/501 ,  C07D471/04 ,  A61K31/496

CPC classification number: A61K31/5377 ,  A61K31/437 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/519 ,  C07D471/04 ,  C07D487/04 ,  Y02A50/463

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, A1, A2, A3, A4, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，R2，A1，A2，A3，A4，X和Y具有说明书中定义的任何值及其药学上可接受的盐，其可用作 治疗疾病和病症，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US20170157104A1

公开(公告)日：2017-06-08

申请号：US15431069

申请日：2017-02-13

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/438 ,  A61K31/4178 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4418 ,  A61K31/5377 ,  A61K31/4355 ,  A61K45/06 ,  A61K31/4545

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20160222020A1

公开(公告)日：2016-08-04

申请号：US15017802

申请日：2016-02-08

Applicant: AbbVie Inc.

Inventor： Neil Wishart ,  Maria A. Argiriadi ,  David J. Calderwood ,  Anna M. Ericsson ,  Bryan A. Fiamengo ,  Kristine E. Frank ,  Michael M. Friedman ,  Dawn M. George ,  Eric R. Goedken ,  Nathan S. Josephsohn ,  Biqin C. Li ,  Michael J. Morytko ,  Kent D. Stewart ,  Jeffrey W. Voss ,  Grier A. Wallace ,  Lu Wang ,  Kevin R. Woller

IPC: C07D487/14 ,  A61K31/437 ,  C07D471/14 ,  A61K31/4985 ,  A61K45/06

CPC classification number: C07D487/14 ,  A61K31/437 ,  A61K31/4985 ,  A61K45/06 ,  C07D471/14 ,  C07D498/14 ,  C07D513/14

Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

公开(公告)号：US20150210720A1

公开(公告)日：2015-07-30

申请号：US14603043

申请日：2015-01-22

Applicant: AbbVie Inc.

Inventor： Robert J. Altenbach ,  Huaqing Liu ,  Bruce Clapham ,  Ana L. Aguirre ,  Marlon Cowart ,  John R. Koenig ,  Katerina Sarris ,  Marc J. Scanio ,  Kerren K. Swinger ,  Anil Vasudevan ,  Clara I. Villamil ,  Kevin R. Woller

IPC: C07D519/00 ,  C07D493/10 ,  C07D405/12 ,  C07D491/20 ,  C07D307/83 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D519/00 ,  C07D307/83 ,  C07D405/12 ,  C07D407/12 ,  C07D491/048 ,  C07D491/107 ,  C07D491/20 ,  C07D493/10

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，Z1，Z2和n如说明书中所定义，可用于治疗由Tropomysin受体阻止或改善的病症或病症 激酶（Trk）。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

公开(公告)号：US08796328B2

公开(公告)日：2014-08-05

申请号：US13922442

申请日：2013-06-20

Applicant: AbbVie Inc.

Inventor： Arthur Gomtsyan ,  Jerome Daanen ,  Michael E. Kort ,  Philip R. Kym ,  Eric A. Voight ,  Kevin R. Woller

IPC: A01N43/16 ,  A61K31/35

CPC classification number: C07C317/28 ,  A61K31/18 ,  A61K31/192 ,  A61K31/352 ,  A61K31/353 ,  A61K31/436 ,  C07C311/08 ,  C07C2602/08 ,  C07D263/48 ,  C07D311/68 ,  C07D311/96 ,  C07D401/04 ,  C07D417/12 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。